Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort

Abstract Introduction The first complete long-acting antiretroviral therapy (ART) regimen, cabotegravir + rilpivirine long-acting (CAB + RPV LA) injectable, was approved in the US for HIV-1 treatment in individuals on a stable antiretroviral regimen with a viral load < 50 copies/mL, no treatment...

Full description

Bibliographic Details
Main Authors: Michael G. Sension, Laurence Brunet, Ricky K. Hsu, Jennifer S. Fusco, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Lewis McCurdy, Michael B. Wohlfeiler, Gregory P. Fusco
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Infectious Diseases and Therapy
Subjects:
Real-world evidence
Adherence
Cabotegravir
HIV
Long-acting injectable
Rilpivirine
Online Access:https://doi.org/10.1007/s40121-023-00890-2

Internet

https://doi.org/10.1007/s40121-023-00890-2

Similar Items